We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+8.01%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$20.1B
AUM Growth
+$3.5B
Cap. Flow
+$2.5B
Cap. Flow %
12.41%
Top 10 Hldgs %
33.13%
Holding
257
New
120
Increased
40
Reduced
39
Closed
20

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$546M
2
WTW icon
Willis Towers Watson
WTW
+$471M
3
MA icon
Mastercard
MA
+$344M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$240M
5
BBL
BHP Group Plc American Depositary Shares (Each representing two Ordinary Shares)
BBL
+$238M

Top Sells

Rank Stock Value
1
TIF
Tiffany & Co.
TIF
+$301M
2
NYT icon
New York Times
NYT
+$209M
3
V icon
Visa
V
+$194M
4
ELV icon
Elevance Health
ELV
+$145M
5
ABBV icon
AbbVie
ABBV
+$123M

Sector Composition

Rank Sector Weight
1 Healthcare 35.71%
2 Technology 14.95%
3 Financials 13.65%
4 Communication Services 11.15%
5 Industrials 7.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBIO
51
DELISTED
Generation Bio
GBIO
$93.1M 0.46%
327,050
+100,168
+44% +$32.1M
PCG icon
52
PG&E
PCG
$38.8B
$85.4M 0.42%
7,292,042
– –
KRTX
53
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$81.2M 0.4%
675,000
-25,000
-4% -$2.83M
CLGX
54
DELISTED
Corelogic, Inc.
CLGX
$77.3M 0.38%
975,000
+400,972
+70% +$32M
BCAB icon
55
BioAtla
BCAB
$5.3M
$75.9M 0.38%
29,841
-9,500
-24% -$24.4M
BRMK
56
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$75M 0.37%
7,170,213
– –
RVMD icon
57
Revolution Medicines
RVMD
$44.9B
$73.9M 0.37%
+1,609,730
New +$72.2M
BPMC
58
DELISTED
Blueprint Medicines
BPMC
$67.6M 0.34%
+694,791
New +$69.4M
AGIO icon
59
Agios Pharmaceuticals
AGIO
$1.98B
$64.5M 0.32%
1,250,000
+250,000
+25% +$12.4M
KSU
60
DELISTED
Kansas City Southern
KSU
$63.3M 0.31%
240,000
-114,400
-32% -$24.9M
PTGX icon
61
Protagonist Therapeutics
PTGX
$9.99B
$62.8M 0.31%
2,425,000
– –
ARNA
62
DELISTED
Arena Pharmaceuticals Inc
ARNA
$59M 0.29%
850,000
+100,000
+13% +$7.69M
KYNB
63
Kyntra Bio
KYNB
$30.4M
$58.4M 0.29%
67,348
-8,652
-11% -$9.21M
CYTK icon
64
Cytokinetics
CYTK
$10.7B
$58.1M 0.29%
2,500,000
+100,000
+4% +$2.14M
PRAH
65
DELISTED
PRA Health Sciences, Inc.
PRAH
$53.7M 0.27%
+350,000
New +$47.5M
TVRD
66
Tvardi Therapeutics
TVRD
$24.8M
$53.5M 0.27%
68,472
– –
APHA
67
DELISTED
Aphria Inc. Common Shares
APHA
$50.8M 0.25%
+2,765,800
New +$44.8M
KRYS icon
68
Krystal Biotech
KRYS
$10.3B
$48.1M 0.24%
625,000
+100,000
+19% +$7.27M
LNTH icon
69
Lantheus
LNTH
$6.53B
$48.1M 0.24%
2,250,000
-400,000
-15% -$7.26M
BEAM icon
70
Beam Therapeutics
BEAM
$3.07B
$47.4M 0.24%
+592,481
New +$56.4M
TPTX
71
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$47.3M 0.24%
+500,000
New +$59.5M
ATTO
72
DELISTED
Atento S.A.
ATTO
$46.8M 0.23%
2,230,357
– –
RDUS
73
DELISTED
Radius Health, Inc.
RDUS
$44M 0.22%
2,107,400
– –
ZGNX
74
DELISTED
Zogenix, Inc.
ZGNX
$43.9M 0.22%
2,250,000
– –
ANNX icon
75
Annexon
ANNX
$961M
$40.5M 0.2%
1,455,846
-101,415
-7% -$2.79M
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q1 2021 Portfolio in Review

As of Q1 2021, Thomas Steyer held 257 positions worth $20.1B, up 21% from $16.6B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Thomas Steyer deployed $2.5B of net new capital in Q1 2021, opening 120 new positions and adding to 40 existing holdings. Its largest new stake was Mastercard: 985,920 shares worth $351M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 39% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was New York Times, an estimated $209M trimmed.

  • Thomas Steyer's largest Q1 2021 buy was Mastercard: 985,920 shares worth $351M.
  • Thomas Steyer added most to Alexion Pharmaceuticals in Q1 2021, an estimated $546M increase.
  • Thomas Steyer's biggest Q1 2021 reduction was New York Times, cutting an estimated $209M.
  • Thomas Steyer fully exited Tiffany & Co. in Q1 2021, selling an estimated $301M.
  • Thomas Steyer's ten largest holdings make up 33% of its $20.1B portfolio in Q1 2021.
  • Thomas Steyer opened 120 new positions and closed 20 in Q1 2021.
  • Thomas Steyer's portfolio value rose 21% quarter-over-quarter to $20.1B.

Based on Farallon Capital Management's 13F filing for Q1 2021, filed 17 May 2021.